Journal article

CAR-T cell therapy: practical guide to routine laboratory monitoring

Adrian G Selim, Adrian Minson, Piers Blombery, Michael Dickinson, Simon J Harrison, Mary Ann Anderson

PATHOLOGY | ELSEVIER | Published : 2021


Chimeric antigen receptor (CAR)-T cell therapy is a genetically-modified cellular immunotherapy that has a current established role in the treatment of relapsed/refractory B-cell acute lymphoblastic leukaemia and diffuse large B-cell lymphoma, with emerging utility in a spectrum of other haematological and solid organ malignancies. It is associated with a number of characteristic toxicities, most notably cytokine release syndrome and neurotoxicity, for which laboratory testing can aid in the prediction of severity and in monitoring. Other toxicities, such as cytopenias/marrow hypoplasia, hypogammagloblinaemia and delayed immune reconstitution are recognised and require monitoring due to the ..

View full abstract